X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs PLETHICO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES PLETHICO PHARMA ALKEM LABORATORIES/
PLETHICO PHARMA
 
P/E (TTM) x - -1.1 - View Chart
P/BV x 6.1 0.0 36,500.9% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALKEM LABORATORIES   PLETHICO PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
PLETHICO PHARMA
Mar-14
ALKEM LABORATORIES/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589395 402.4%   
Low Rs1,23231 3,936.1%   
Sales per share (Unadj.) Rs417.5604.4 69.1%  
Earnings per share (Unadj.) Rs56.332.5 173.3%  
Cash flow per share (Unadj.) Rs64.751.3 126.1%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.9473.6 61.9%  
Shares outstanding (eoy) m119.5734.08 350.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.4 958.3%   
Avg P/E ratio x25.16.6 381.9%  
P/CF ratio (eoy) x21.84.2 525.0%  
Price / Book Value ratio x4.80.5 1,070.0%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6537,262 2,322.3%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1711,596 574.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,91520,598 242.3%  
Other income Rs m1,645386 425.8%   
Total revenues Rs m51,56120,984 245.7%   
Gross profit Rs m8,4822,818 301.0%  
Depreciation Rs m1,006642 156.6%   
Interest Rs m6711,593 42.1%   
Profit before tax Rs m8,451969 872.6%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606-138 -1,160.6%   
Profit after tax Rs m6,7311,107 608.1%  
Gross profit margin %17.013.7 124.2%  
Effective tax rate %19.0-14.3 -133.0%   
Net profit margin %13.55.4 250.9%  
BALANCE SHEET DATA
Current assets Rs m27,06218,877 143.4%   
Current liabilities Rs m15,32411,896 128.8%   
Net working cap to sales %23.533.9 69.4%  
Current ratio x1.81.6 111.3%  
Inventory Days Days6736 185.1%  
Debtors Days Days41198 20.9%  
Net fixed assets Rs m12,6109,861 127.9%   
Share capital Rs m239341 70.2%   
"Free" reserves Rs m34,49012,331 279.7%   
Net worth Rs m35,02716,139 217.0%   
Long term debt Rs m1,2124,706 25.7%   
Total assets Rs m54,38733,146 164.1%  
Interest coverage x13.61.6 846.0%   
Debt to equity ratio x00.3 11.9%  
Sales to assets ratio x0.90.6 147.7%   
Return on assets %13.68.1 167.1%  
Return on equity %19.26.9 280.2%  
Return on capital %24.912.3 202.3%  
Exports to sales %12.921.4 60.6%   
Imports to sales %3.115.2 20.3%   
Exports (fob) Rs m6,4614,402 146.8%   
Imports (cif) Rs m1,5403,136 49.1%   
Fx inflow Rs m6,5634,402 149.1%   
Fx outflow Rs m3,0123,184 94.6%   
Net fx Rs m3,5521,219 291.5%   
CASH FLOW
From Operations Rs m7,2592,437 297.8%  
From Investments Rs m1,864-6,265 -29.8%  
From Financial Activity Rs m-9,2732,490 -372.4%  
Net Cashflow Rs m-150-1,337 11.2%  

Share Holding

Indian Promoters % 66.9 82.7 80.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 4.3 769.8%  
FIIs % 0.0 5.5 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 7.5 -  
Shareholders   68,381 10,665 641.2%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  NATCO PHARMA  ELDER PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - NOVARTIS COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS